💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

Subject: Biotech and Medical Sciences

  • Evolution of Genomic Medicine: Research to Mainstream Healthcare

    genomic medicine

    Central Idea

    • Over the past two decades, genomics and the use of genetic information in healthcare have undergone significant transformations.
    • Once limited to major research centers, personal genome sequencing has become widely accessible, empowering individuals with detailed knowledge of their genetic makeup.

    What is genome sequencing?

    • Genome sequencing is the process of determining the complete DNA sequence of an organism’s genome.
    • The genome is the entire set of genetic material (DNA in the case of most organisms) that provides the instructions for building, maintaining, and functioning of the organism.
    • Genome sequencing involves identifying the order of nucleotides (adenine, thymine, cytosine, and guanine) in an organism’s DNA.

    Applications of Personal Genome Sequencing

    • Disease Risk Assessment: Personal genome sequencing can identify genetic variants associated with an increased risk of certain diseases, such as cardiovascular conditions, cancer, and neurodegenerative disorders.
    • Pharmacogenomics: Personal genome sequencing helps predict how an individual will respond to specific medications, allowing for the customization of drug prescriptions based on genetic factors.
    • Cancer Genomics: Personal genome sequencing of cancer cells helps identify specific mutations driving tumor growth.
    • Rare Genetic Disorders: Personal genome sequencing is a powerful tool for diagnosing rare genetic disorders, particularly in cases where traditional diagnostic methods may be inconclusive.
    • Reproductive Health: Couples planning to have children can undergo personal genome sequencing to assess the risk of passing on genetic conditions to their offspring.
    • Forensic Identification: Personal genome sequencing can be used in forensics for human identification and the resolution of criminal investigations.
    • Research and Scientific Discovery: Aggregated personal genomic data from large populations contribute to ongoing research, advancing our understanding of the genetic basis of diseases and human biology.

    Case Study: Iceland’s Genetics Research

    • Iceland’s Unique Demographics: Iceland’s historical demographic isolation and early initiation of population-level genome sequencing have made it a focal point in genetics research.
    • Research on Lifespan and Genetic Variants: A study in Iceland suggested that actionable incidental genetic variants could potentially improve lifespan, with significant findings related to cancer-related genotypes.

    Future of Genome Sequencing and Healthcare

    • Increasing Accessibility: As genome sequencing becomes more accessible and affordable, regular population-scale sequencing and newborn sequencing initiatives are becoming more feasible.
    • Benefits for Population Health: Widespread implementation of these programs could provide medically actionable insights, enabling proactive and effective disease treatment and prevention.
    • Advancements in Technology: Current genome sequencing technologies, often referred to as second-generation sequencing, have limitations in handling repetitive sequences and resolving structural variations. Third-generation sequencing technologies, such as single-molecule sequencing, are expected to overcome these challenges and provide longer read lengths, improving the accuracy and completeness of genome sequences.

    Conclusion

    • The advancements in genomics are paving the way for a more proactive and personalized approach to healthcare, with significant potential for disease prevention and management.

  • Huntington’s Disease: Insights from Medical Genetics and Fruit Fly Research

    Central Idea

    • The Nizam’s Institute of Medical Sciences in Hyderabad reports three to four cases of Huntington’s disease monthly, with each case impacting entire families.

    Understanding Huntington’s Disease  

    Details
    Nature of Disorder Genetic, progressive brain disorder
    Genetic Cause Mutation in the huntingtin gene on chromosome 4
    Inheritance Pattern Autosomal dominant disorder (only one copy of the defective gene, from either parent, is enough for disease onset)
    Symptoms Movement Disorders: Involuntary movements (chorea), muscle problems (dystonia), abnormal eye movements.

    Cognitive Disorders: Difficulty in organizing and focusing, lack of flexibility, impulse control issues.

    Psychiatric Disorders: Depression, mood swings, changes in personality
    Age of Onset Typically between 30 and 50 years of age, but can vary widely

    Gradual onset, worsening over 10-25 years, leading to severe disabilities
    Diagnosis Genetic testing to detect the presence of the defective gene
    Treatment No cure; treatment focuses on managing symptoms, including medication for movement and psychiatric disorders, and therapy
    Impact on Life Expectancy Can shorten life expectancy, particularly if onset is at a younger age

     

    Role of the HTT Gene and Glutamine Repeats

    • Genetic Mutation: Huntington’s disease is caused by a mutation in the HTT gene, leading to abnormal huntingtin (Htt) proteins that damage neurons.
    • Polyglutamine Tracts: The severity of the disease correlates with the length of glutamine repeats in the Htt protein; longer repeats result in earlier and more severe symptoms.
    • Inheritance Pattern: The disease manifests even if only one copy of the HTT gene is mutated, demonstrating its dominant nature.
    • Similar Proteins and Diseases: Other proteins with polyglutamine tracts, when mutated, can also cause neuronal degeneration, leading to disorders like spinocerebellar ataxia.

    Fruit Fly Study: A Model for Understanding Huntington’s

    • Genetic Engineering in Flies: Researchers engineered fruit flies to express the human HTT gene with extended polyglutamine tracts in their neurons.
    • Gal4/UAS System: Utilizing the Gal4 gene from baker’s yeast, the study induced expression of mutated HTT in fly neurons.
    • Symptoms in Flies: Flies with longer glutamine tracts exhibited symptoms similar to Huntington’s disease, unlike those with shorter, normal tracts.

    Yod1 Gene Discovery

    • Gene Expression Experiment: The study explored the effects of altering the expression of 32 genes on disease-like symptoms in fruit flies.
    • Yod1’s Protective Role: Overexpression of the Yod1 gene eliminated neurodegeneration and other disease-like effects in flies with longer glutamine tracts.

    Broader Implications and Future Research

    • Potential in Human Treatment: If overexpression of the human version of Yod1 shows similar benefits in fruit flies, it could be a promising avenue for treating Huntington’s in humans.
    • Value of Model Organisms: Studies in fruit flies and yeasts are pivotal for understanding molecular mechanisms of diseases like Huntington’s.

  • New COVID Variant ‘JN.1’

    Central Idea

    • Following the detection of the JN.1 COVID-19 variant, Karnataka announced that senior citizens are advised to wear masks.
    • The JN.1 variant was identified in Kerala and in a traveler from Singapore to Tamil Nadu, with additional cases found in Goa.

    Understanding the JN.1 Variant

    • Variant Lineage: JN.1 is a sub-variant of BA.2.86, also known as Pirola, first detected in the United States in September and globally as early as January.
    • Mutation Characteristics: While JN.1 has only one additional mutation on the spike protein compared to Pirola, its high number of spike protein mutations has drawn attention of researchers.

    Potential Impact of JN.1

    • Transmission and Severity: Currently, there is no evidence suggesting that JN.1 causes more severe symptoms or spreads faster than other circulating variants.
    • WHO Assessment: Both Pirola and JN.1 have been effectively neutralized by serum from infected and vaccinated individuals, according to the WHO Technical Advisory Group on COVID-19 Vaccine Composition.

    Global Spread and Current Concerns

    • Increasing Cases: A rise in cases caused by Pirola and JN.1 has been observed globally, including in the USA, Europe, Singapore, and China.
    • WHO Data: JN.1 accounted for a significant proportion of COVID-19 sequences in the GISAID database and a notable percentage of variants in the United States.
    • Singapore’s Situation: Singapore reported a surge in COVID-19 cases, predominantly JN.1, with increased hospitalizations among older individuals.

    Vaccination and Immunity in India

    • Hospitalization Risk: Data from Singapore indicates higher hospitalization risks for those who received their last COVID-19 vaccine dose over a year ago.
    • Indian Immunity Levels: Doctors suggests that widespread vaccination and exposure to COVID-19 have likely resulted in substantial immunity in India, reducing the need for updated vaccines.
    • Consistent Precautions: Experts recommend standard protective measures against respiratory viruses, including masking in crowded and enclosed spaces, staying in well-ventilated areas, and frequent hand washing.

  • CRISPR-Based Therapies: A New Era in Genetic Disease Treatment

    Central Idea

    • Revolutionary Development: The medical world is witnessing a significant breakthrough with the approval of CRISPR-based therapies for sickle-cell disease and β-thalassemia in the U.K. and the U.S.
    • Global Impact: These advancements hold the potential to transform the lives of millions suffering from these inherited blood disorders.

    CRISPR Technology: From Discovery to Application

    • Origins of CRISPR: Discovered in archaea in 1993, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) elements were later found to form an antiviral defense system in bacteria with Cas (CRISPR-associated) proteins.
    • Nobel Prize-Winning Innovation: Emmanuelle Charpentier and Jennifer Doudna’s work on CRISPR-Cas9 as a ‘molecular scissor’ earned them the 2020 Nobel Prize in chemistry.
    • Eukaryotic Genome Editing: Subsequent research demonstrated CRISPR-Cas9’s ability to edit eukaryotic genomes, paving the way for various applications in genetic therapies and agriculture.

    CRISPR in Medicine: Recent Approvals and Applications

    • CRISPR-Based Treatment for Blood Disorders: The MHRA in the U.K. and the FDA in the U.S. approved ‘Casgevy’ for treating sickle-cell disease and transfusion-dependent β-thalassemia.
    • Treatment Mechanism: Casgevy involves modifying a patient’s blood stem cells to correct the genetic defect causing sickling, then regrafting them to produce normal red blood cells.
    • Historical Context: This approval marks a full circle from Linus Carl Pauling’s description of sickle-cell disease as a molecular disorder 74 years ago.

    Emerging CRISPR Technologies and Approaches

    • Base-Editing: This technique allows genome editing at the single nucleotide level.
    • Prime Editing: A newer method that uses a search-and-replace strategy for precise genome modifications.
    • Epigenetic Modifications: CRISPR systems are also being developed to target epigenetic effects.

    Challenges and Future Prospects

    • Safety and Accuracy Concerns: Issues like off-target events, where CRISPR-Cas9 edits unintended parts of the genome, pose significant challenges.
    • Balancing Risks and Benefits: While the potential of these technologies is enormous, their risks must be weighed against both short- and long-term benefits.
    • Ongoing Research and Surveillance: Continuous scrutiny is essential to uncover potential side effects that are currently unknown.

    Conclusion

    • Celebrating Advances: The approval of therapies like Casgevy heralds a new era for millions suffering from genetic diseases.
    • Optimistic Outlook: The advancements in CRISPR technology signal a promising future in the field of genetic medicine and disease treatment.

  • The regulator’s challenge in the age of AI

    Global Competition for AI Regulation, or a Framework for AI Diplomacy? – The Diplomat

    Central idea 

    The central idea revolves around the global momentum for AI regulation, acknowledging its transformative impact on sectors. It emphasizes the urgent need for regulatory skill-building to match the evolving risks of AI, especially for regulatory agencies, while highlighting the potential widespread adoption and diverse applications of generative AI across the economy.

    Key Highlights:

    • Recent Global Efforts: Global initiatives, including executive orders, legislations, and declarations, underscore the importance of regulatory skill-building in the digital age.
    • Transformative Impact: The urgency to rethink regulatory capabilities arises from AI’s transformative impact on sectors like banking, telecommunications, and insurance.
    • Generative AI Products: Products showcase vast scope and rapid improvement, indicating potential widespread adoption across the economy.

    Key Challenges:

    • Urgent Skill-Building: The downstream challenge involves urgently building regulatory skills to match the pace of emerging risks from AI technology.
    • Regulatory Agencies’ Role: Regulatory agencies, at the forefront, must adapt to AI’s transformative influence in various sectors.

    Key Terms and Phrases:

    • Generative AI: AI products with the capability to generate content or services, showcasing vast scope and rapid improvement.
    • Algorithmic Auditing: Audit of each part of a model’s lifecycle to understand workings and identify potential problematic outcomes.

    Key Quotes:

    • “AI may alter professional practices and norms, reshaping industries such as bookkeeping, accounting, and law.”
    • “Effective regulation can facilitate market acceptance of AI products and services, necessitating a proactive regulatory approach.”

    Key Statements:

    • Regulatory agencies, like the Reserve Bank of India and the Securities and Exchange Board of India, are developing AI tools for regulatory supervision.
    • Building regulatory capabilities in-house is challenging; agencies need to be nimble and proactive to acquire necessary skills and evaluate external inputs.

    Key Examples and References:

    • Banks and credit card companies are using AI for fraud detection, risk assessment, and digital marketing.
    • The Indian insurance industry utilizes AI for risk management, indicating diverse applications of AI in the economy.

    Key Facts and Data:

    • The Economist Intelligence Unit reports AI usage in banks, credit card companies, and e-commerce for various purposes, highlighting the technology’s growing influence.

    Critical Analysis:

    • The transformative potential of AI in various sectors necessitates a reevaluation of regulatory capabilities, including algorithmic auditing and understanding disclosure-related requirements.
    • While private sector incentives may mitigate rapid AI adoption, effective regulation remains crucial for market acceptance and avoiding inadequate reliance on external expertise.

    Way Forward:

    • Regulators must proactively build capabilities to understand and implement AI regulations, emphasizing the need for systemic development at the scale of the Indian state.
    • The central government should take the lead in understanding and replicating the transition from an analog to a digital state, addressing the challenge of developing capabilities for AI regulation.

  • Population-Level Genome Sequencing and Its Impact

    ‘deCODE’ Initiative

    Central Idea

    • The UK recently completed sequencing half a million whole genomes, nearly 0.7% of its population, under ‘deCODE’ Initiative.
    • Various countries have launched large-scale genome projects, with some focusing on specific populations like African ancestry.

    About ‘deCODE’ Initiative

    • Inception: Launched in Iceland in 1996, deCODE genomics enrolled most of the Icelandic population for genetic studies.
    • Contributions: The initiative enhanced disease genetics understanding and set standards for handling genomic data, integrating medical records with genealogies.

    Merit of Large-Scale Sequencing

    • Disease Research and Understanding: Large-scale genome sequencing allows researchers to identify genetic variations associated with various diseases. This information is crucial for understanding the genetic basis of diseases, including rare genetic disorders and complex conditions like cancer.
    • Personalized Therapies: With a better understanding of an individual’s genetic makeup, it becomes possible to develop personalized and targeted therapies. 
    • Genetic Counseling: Large-scale genome sequencing provides valuable information for genetic counseling, helping individuals and families understand their risk for certain genetic conditions.
    • Identification of Rare Variants: Large-scale sequencing efforts contribute to the identification of rare genetic variants that might be responsible for certain diseases. These discoveries are essential for expanding our knowledge of the genetic landscape and improving diagnostic capabilities.
    • Population Genetics and Evolution: Genome sequencing on a large scale allows researchers to study the genetic diversity within populations. This information is valuable for understanding human evolution, migration patterns, and population-specific genetic traits.

    Ethical and Regulatory Challenges

    • Privacy Concerns: Genome sequencing generates highly sensitive and personal information. There is a risk that genetic data could be misused or lead to privacy breaches.
    • Informed Consent: Obtaining informed consent for genome sequencing is complex due to the vast amount of information generated and the potential for incidental findings.
    • Data Ownership and Control: Balancing individual rights with the need for research and medical advancements requires careful consideration of data sharing, ownership, and access policies.
    • Genetic Discrimination: Concerns about genetic discrimination in areas such as employment, insurance, and education may discourage individuals from undergoing genome sequencing. L
    • Access to Genetic Services: Disparities in access to genetic services and genomic technologies may exacerbate existing healthcare inequalities.
    • Ethical Use of Genetic Data in Research: Researchers must adhere to ethical standards when using genetic data in research. This includes obtaining proper consent, ensuring data security, and transparently communicating the purpose and potential risks of the research.

    Long-Term Impact and Future Prospects

    • Beyond Individual Health: Population-scale genomics will enhance our understanding of human evolution, migration, and adaptation.
    • Personalized Medicine: It paves the way for personalized healthcare based on individual genetic profiles.
    • Billion Genome Project: The possibility of sequencing a billion genomes in a single project is on the horizon, alongside individuals’ rights to access and understand their own genomic data.

    Conclusion

    • Population-scale genomics is at the forefront of a genomic revolution, with the potential to transform healthcare, deepen our understanding of human biology, and shape our approach to medicine and biology.
    • This evolving field promises to bring personalized, precise treatments and a richer comprehension of our genetic heritage.

  • Embryonic Development: Unraveling the Mysteries of HERVH and ‘Jumping Genes’

    Central Idea

    • Recent breakthroughs in genetic research have shed light on the complexities of early embryonic development, particularly focusing on the inner cell mass, a key component in forming the human body.

    Embryonic Development Explained

    • Life’s Commencement: Life begins with the fusion of sperm and egg, creating a zygote, the first cell of a new individual.
    • Cellular Multiplication: The zygote undergoes rapid cell division, marking the onset of embryonic development.
    • Diverse Cell Differentiation: As the embryo develops, cells differentiate into various types, leading to the formation of organs and tissues.
    • Journey to Birth: This intricate process culminates in the birth of a newborn after nine months of gestation.

    Early Stages of Development

    • Inner Cell Mass Formation: Early embryonic cells cluster around the inner cell mass, vital for the embryo’s development.
    • Pluripotency of Cells: These cells are pluripotent, meaning they can develop into any cell type in the body.
    • Scientific Focus: The inner cell mass is a primary subject of study due to its critical role in human development.

    Gene Expression in Embryonic Cells

    • Analyzing Gene Activity: Researchers study the proteins produced by genes to understand cell-specific gene expression.
    • Deciphering Cell Development: This research provides insights into the active genes in each cell, revealing the mechanisms of cell development.

    Discoveries in the Inner Cell Mass

    • 2016 Research Insights: Manvendra Singh’s reanalysis of gene expression data identified a new group of non-committed cells in the inner cell mass.
    • Enigma of Cell Death: These cells, unlike others, do not progress to later developmental stages and are eliminated early on.

    HERVH Gene and Cell Survival

    • HERVH’s Crucial Function: A 2014 study revealed that HERVH, a gene with virus-like properties, is essential for maintaining pluripotency in embryonic stem cells.
    • Gene Expression Variations: Singh’s research showed that while most inner cell mass cells express HERVH, the non-committed cells that eventually die do not.
    • Independent Confirmation: This discovery was corroborated by researchers at the University of Spain in lab-fertilized embryos.

    Understanding ‘Jumping Genes’

    • Transposons in Non-Committed Cells: The non-committed cells express transposons, or ‘jumping genes’, which can cause DNA damage and lead to cell death.
    • HERVH’s Protective Role: HERVH protects most cells from the harmful effects of transposons, but cells lacking HERVH expression are vulnerable.
    • Natural Selection in Embryos: The early human embryo acts as a selection ground, favoring cells with HERVH expression.
    • HERVH’s Unique Nature: Interestingly, HERVH itself is a transposon but functions protectively rather than destructively.

    Implications for Placenta and Beyond

    • Placental Development: Cells that form the placenta also exhibit transposon activity but manage to survive without HERVH expression.
    • Impact on Regenerative Medicine: Understanding HERVH’s role in cell pluripotency has profound implications for regenerative medicine and could influence embryo viability in fertility treatments.Top of Form

  • Casgevy: Gene Therapy for Sickle Cell Disease and Thalassaemia

    Casgevy

    Central Idea

    • The recent approval of Casgevy, a groundbreaking gene therapy utilizing Crispr-Cas9 technology, by the UK health authorities represents a monumental achievement in medicine.
    • This therapy holds the potential to provide a lifelong cure for individuals grappling with sickle cell disease and thalassaemia, offering newfound hope and possibilities in the field of genetic medicine.

    Casgevy: A Gene-Editing Marvel

    • World’s First Licensed Gene Therapy: Casgevy stands as the world’s inaugural licensed gene therapy employing Crispr-Cas9 technology, an innovation that garnered the Nobel Prize in 2020.
    • Targeting Faulty Genes: This revolutionary therapy specifically targets the flawed genes responsible for sickle cell disease and thalassaemia, offering the tantalizing prospect of a lifelong cure.
    • A Paradigm Shift: In the past, the only permanent treatment option was a bone marrow transplant, contingent on discovering a closely matched donor.

    Mechanism of Action

    • Genetic Errors: Sickle cell disease and thalassaemia both stem from genetic abnormalities within the haemoglobin gene, impairing the structure and functionality of red blood cells.
    • Precision Gene Editing: Casgevy harnesses the patient’s blood stem cells, meticulously edited using Crispr-Cas9, with a specific focus on the BCL11A gene.
    • Boosting Foetal Haemoglobin: By stimulating the production of foetal haemoglobin, which lacks the irregularities found in adult haemoglobin, the therapy mitigates the symptoms of these debilitating conditions.

    Understanding Sickle Cell Disease and Thalassaemia

     

    Sickle Cell Disease: Characterized by crescent-shaped red blood cells, this condition disrupts smooth blood flow, resulting in excruciating pain, infections, anaemia, and even strokes. India bears witness to an annual influx of 30,000-40,000 children born with sickle cell disease.

    Thalassaemia: This disorder leads to diminished haemoglobin levels, causing fatigue, breathlessness, and irregular heartbeats, necessitating lifelong blood transfusions and chelation therapy. India is home to the world’s largest population of children with thalassaemia major, numbering approximately 1-1.5 lakh.

     Clinical Trial Results

    • Clinical trials of Casgevy showcased remarkable results, with participants afflicted by sickle cell disease reporting a substantial reduction in severe pain crises.
    • Those with thalassaemia witnessed a remarkable 70% reduction in the need for blood transfusions.

    Administration and Challenges

    • One-Time Treatment: Casgevy involves a one-time treatment process, encompassing the collection of bone marrow blood stem cells through apheresis, followed by editing and testing over a span of approximately six months.
    • Conditioning Medicine: Prior to the transplant with edited cells, conditioning medicine is administered to clear the bone marrow of existing cells.
    • Challenges: Challenges include the expected high cost of the therapy, potentially around $2 million per patient, and the absence of local manufacturing facilities, necessitating the international transport of blood stem cells.

    Future Prospects

    • Price Reduction: Despite pricing challenges, experts hold the belief that ongoing research will lead to price reductions, making the therapy more accessible. Local manufacturing facilities are also anticipated to emerge.
    • Indian Research: Researchers in India are actively pursuing gene therapies for sickle cell disease, with clinical trials on the horizon in the coming years.

  • FDA Approves World’s First Chikungunya Vaccine: Ixchiq

    Central Idea

    • The Food and Drug Administration (FDA) in the US granted approval for the world’s inaugural vaccine against chikungunya.

    Ixchiq: The Chikungunya Vaccine

    • Developed by European vaccine manufacturer Valneva, this vaccine will be available under the brand name Ixchiq.
    • It has been authorized for use in individuals aged 18 and above who are at elevated risk of chikungunya exposure.
    • It is administered as a single dose via injection into the muscle.
    • The vaccine contains a live, attenuated (weakened) form of the chikungunya virus. It may induce symptoms similar to those experienced by individuals with the disease.

    Understanding Chikungunya

    • Symptoms: Chikungunya is characterized by severe joint pain, limited mobility, and accompanying fever. It is a viral infection (CHIKV) primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes, earning it the status of an “emerging global health threat.”
    • Global Prevalence: Chikungunya is prevalent in Africa, Asia, and the Americas, with sporadic outbreaks reported in other regions. Since 2004, outbreaks have become more frequent and widespread, partly due to viral adaptations facilitating transmission by Aedes albopictus mosquitoes.
    • Symptoms: Alongside joint pain, chikungunya symptoms include joint swelling, muscle pain, headache, nausea, fatigue, and rash. While severe cases and deaths are rare, they may be underreported due to misdiagnosis, often confused with dengue or zika.
    • No Cure: Currently, there is no cure for chikungunya, and treatment is primarily focused on symptomatic relief, including analgesics for pain, antipyretics for fever, rest, and adequate fluid intake.
    • Prevention: Prevention efforts primarily revolve around mosquito control through public health initiatives, civic maintenance, and personal measures such as using medicated mosquito nets and eliminating stagnant water sources to hinder mosquito breeding.

  • H. Pylori Detection and Drug-Resistance Identification

    H. Pylori

    Central Idea

    • Indian researchers have developed a groundbreaking two-step PCR-based assay for detecting Helicobacter pylori (H. pylori) infection, determining clarithromycin resistance, and distinguishing drug-sensitive strains.
    • This molecular diagnostic tool reduces the detection time from weeks to just six-seven hours and exhibits remarkable accuracy, boasting 100% sensitivity and specificity.

    About H. Pylori Detection

    • Helicobacter pylori, often abbreviated as H. pylori, is a type of bacteria that can infect the stomach and the upper part of the small intestine.
    • It is a common bacterial infection associated with various gastrointestinal conditions, including gastritis (inflammation of the stomach lining) and peptic ulcers (sores or lesions in the lining of the stomach or the duodenum, which is the first part of the small intestine).

    Why discuss this?

    • Increasing Resistance: India faces a growing challenge of clarithromycin-resistant H. pylori strains, resulting in decreased treatment efficacy.
    • Asymptomatic Infections: While most H. pylori infections are asymptomatic, 10–15% of cases lead to peptic ulcer disorders or stomach cancer.
    • Prevalence in India: H. pylori infections affect 60-70% of the Indian population, acquired in childhood and persisting if not treated.
    • Gastric Cancer Risk: H. pylori infection is a significant risk factor for gastric cancer.

    Understanding Drug Resistance Mechanism in H. Pylori

    • Genome Sequencing: Researchers identified a point mutation (A to G mutation at position 2143) in the 23S ribosomal RNA (rRNA) gene as the cause of clarithromycin resistance.
    • Confirmation: They isolated and transferred the 617 base pairs containing the mutation to drug-sensitive bacteria, which became resistant, confirming the mutation’s role.
    • Published Findings: The study’s results were published in the journal Gut Pathogens.
    • Exploring Binding Affinity: Bioinformatics analysis revealed that drug-resistant strains had weaker binding affinity to clarithromycin compared to drug-sensitive strains.
    • Impact of Weak Binding: Weaker binding limits the drug’s penetration into bacteria, rendering it ineffective against resistant strains.

    Development of the PCR-Based Assay

    • Biopsy Samples: The DNA template used for the assay was prepared by amplifying a small segment containing the point mutation directly from biopsy samples.
    • Validation: DNA templates from cultured bacteria were compared with those from biopsy samples to validate their accuracy.
    • Two-Step PCR: The assay employs a two-step PCR approach to detect H. pylori infection and differentiate resistant from sensitive isolates.
    • Allele-Specific Primers: Resistant-specific and sensitive-specific primers exploit the point mutation for selective amplification.
    • High Accuracy: Evaluation against conventional methods and sequencing analysis demonstrated 100% sensitivity and specificity.